Doris Benbrook to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Doris Benbrook has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.726
-
Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents. Gynecol Oncol. 2009 Dec; 115(3):438-42.
Score: 0.260
-
Retinoids enhance cisplatin-based chemoradiation in cervical cancer cells in vitro. Gynecol Oncol. 2002 Apr; 85(1):223-5.
Score: 0.155
-
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
Score: 0.117
-
Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecol Oncol. 2014 Apr; 133(1):11-5.
Score: 0.089
-
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50.
Score: 0.070
-
Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. Gynecol Oncol. 2021 01; 160(1):302-311.
Score: 0.035